clearvise AG (DUSE:ABO)
Germany · Delayed Price · Currency is EUR | Market Cap | 126.60M |
| Revenue (ttm) | 35.10M |
| Net Income (ttm) | -1.46M |
| Shares Out | n/a |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | 58.23 |
| Dividend | 0.06 (4.29%) |
| Ex-Dividend Date | Jul 7, 2025 |
| Volume | 450 |
| Average Volume | 2,389 |
| Open | 1.430 |
| Previous Close | 1.490 |
| Day's Range | 1.380 - 1.430 |
| 52-Week Range | 1.380 - 1.850 |
| Beta | n/a |
| RSI | 21.59 |
| Earnings Date | Aug 12, 2025 |
About Achilles Therapeutics
clearvise AG operates as an independent electricity producer from renewable energies in Europe. Its operational portfolio consists of wind and solar parks, and a biogas plant in four countries with an installed capacity of approximately 303 MW. The company was formerly known as ABO Invest AG and changed its name to clearvise AG in 2020. clearvise AG was founded in 2011 and is based in Wiesbaden, Germany. [Read more]
Financial Performance
In 2024, clearvise AG's revenue was 36.08 million, a decrease of -19.53% compared to the previous year's 44.84 million. Earnings were 724,000, a decrease of -89.41%.
Financial StatementsNews
EQS-News: clearvise AG: 2025 Annual General Meeting approves dividend payment
EQS-News: clearvise AG / Key word(s): AGM/EGM clearvise AG: 2025 Annual General Meeting approves dividend payment 04.07.2025 / 18:30 CET/CEST The issuer is solely responsible for the content of this a...
EQS-Adhoc: clearvise AG: Chief Executive Officer considers stepping down from the Management Board at the end of her current term of office on 28 February 2026
EQS-Ad-hoc: clearvise AG / Key word(s): Personnel clearvise AG: Chief Executive Officer considers stepping down from the Management Board at the end of her current term of office on 28 February 2026 3...